BACKGROUND: Noroviruses cause significant morbidity and mortality from acute gastroenteritis in all age groups worldwide. METHODS: We conducted 2 phase 1 double-blind, controlled studies of a virus-like particle (VLP) vaccinederived from norovirus GI.1 genotype adjuvanted with monophosphoryl lipid A (MPL) and the mucoadherent chitosan. Healthy subjects18-49 years of age were randomized to 2 doses of intranasal Norwalk VLP vaccine or controls 21 days apart. Study 1 evaluated 5-, 15-, and 50-μg dosages of Norwalk antigen, and study 2 evaluated 50- and 100-μg dosages. Volunteers recorded symptoms for 7 days after dosing, and safety was followed up for 180 days. Blood samples were collected for serological profile, antibody secreting cells (ASCs), and analysis of ASC homing receptors. RESULTS: The most common symptoms were nasal stuffiness, discharge, and sneezing. No vaccine-related serious adverse events occurred. Norwalk VLP-specific immunoglobulin G and immunoglobulin A antibodies increased 4.8- and 9.1-fold, respectively, for the 100-μg dosage level. All subjects tested who received the 50- or 100-μg vaccine dose developed immunoglobulin A ASCs. These cells expressed molecules associated with homing to mucosal and peripheral lymphoid tissues. CONCLUSIONS: The intranasal monovalent adjuvanted Norwalk VLP vaccine was well tolerated and highly immunogenic and is a candidate for additional study.
RCT Entities:
BACKGROUND: Noroviruses cause significant morbidity and mortality from acute gastroenteritis in all age groups worldwide. METHODS: We conducted 2 phase 1 double-blind, controlled studies of a virus-like particle (VLP) vaccine derived from norovirus GI.1 genotype adjuvanted with monophosphoryl lipid A (MPL) and the mucoadherent chitosan. Healthy subjects 18-49 years of age were randomized to 2 doses of intranasal Norwalk VLP vaccine or controls 21 days apart. Study 1 evaluated 5-, 15-, and 50-μg dosages of Norwalk antigen, and study 2 evaluated 50- and 100-μg dosages. Volunteers recorded symptoms for 7 days after dosing, and safety was followed up for 180 days. Blood samples were collected for serological profile, antibody secreting cells (ASCs), and analysis of ASC homing receptors. RESULTS: The most common symptoms were nasal stuffiness, discharge, and sneezing. No vaccine-related serious adverse events occurred. Norwalk VLP-specific immunoglobulin G and immunoglobulin A antibodies increased 4.8- and 9.1-fold, respectively, for the 100-μg dosage level. All subjects tested who received the 50- or 100-μg vaccine dose developed immunoglobulin A ASCs. These cells expressed molecules associated with homing to mucosal and peripheral lymphoid tissues. CONCLUSIONS: The intranasal monovalent adjuvanted Norwalk VLP vaccine was well tolerated and highly immunogenic and is a candidate for additional study.
Authors: K L Kotloff; F R Noriega; T Samandari; M B Sztein; G A Losonsky; J P Nataro; W D Picking; E M Barry; M M Levine Journal: Infect Immun Date: 2000-03 Impact factor: 3.441
Authors: Mushtaq Ahmed; Douglas M Smith; Tarek Hamouda; Javier Rangel-Moreno; Ali Fattom; Shabaana A Khader Journal: Vaccine Date: 2017-07-31 Impact factor: 3.641
Authors: Gabriel I Parra; Eugenio J Abente; Carlos Sandoval-Jaime; Stanislav V Sosnovtsev; Karin Bok; Kim Y Green Journal: J Virol Date: 2012-04-24 Impact factor: 5.103
Authors: Luigi Buonaguro; Maria Tagliamonte; Maria Luisa Visciano; Hanne Andersen; Mark Lewis; Ranajit Pal; Maria Lina Tornesello; Ulf Schroeder; Jorma Hinkula; Britta Wahren; Franco M Buonaguro Journal: Clin Vaccine Immunol Date: 2012-03-29
Authors: Larissa B Thackray; Erning Duan; Helen M Lazear; Amal Kambal; Robert D Schreiber; Michael S Diamond; Herbert W Virgin Journal: J Virol Date: 2012-10-03 Impact factor: 5.103